The K<sub>Ca</sub>2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.

Diness, Jonas Goldin; Kirchhoff, Jeppe Egedal; Speerschneider, Tobias; Abildgaard, Lea; Edvardsson, Nils; Sørensen, Ulrik S; Grunnet, Morten; Bentzen, Bo Hjorth

The K_Ca2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.

Diness, Jonas Goldin; Kirchhoff, Jeppe Egedal; Speerschneider, Tobias; Abildgaard, Lea; Edvardsson, Nils; Sørensen, Ulrik S; Grunnet, Morten; Bentzen, Bo Hjorth.

Afiliação

Diness JG; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.
Kirchhoff JE; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.
Speerschneider T; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.
Abildgaard L; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Edvardsson N; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.
Sørensen US; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.
Grunnet M; Department of Molecular and Clinical Medicine/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Bentzen BH; Department of In Vivo Pharmacology, Acesion Pharma, Copenhagen, Denmark.

Front Pharmacol ; 11: 159, 2020.

Article em En | MEDLINE | ID: mdl-32180722